Skip to main content
Erschienen in: Diabetologia 12/2005

01.12.2005 | Article

Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli

verfasst von: N. A. Wahab, L. Schaefer, B. S. Weston, O. Yiannikouris, A. Wright, A. Babelova, R. Schaefer, R. M. Mason

Erschienen in: Diabetologia | Ausgabe 12/2005

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

We quantified the glomerular expression of thrombospondin-1 (THBS1, also known as TSP-1), transforming growth factor beta 1 (TGFB1, also known as TGF-β1) and connective tissue growth factor (CTGF) at each stage of diabetic nephropathy. We also examined the roles of THBS1 and CTGF in mediating high-glucose- and glycated-albumin-induced synthesis of the matrix protein, fibronectin, by mesangial cells.

Methods

THBS1, latent and active TGFB1, and CTGF, were detected by immunohistochemistry and in situ hybridisation in biopsies from 19 insulin-dependent diabetic patients with incipient, manifest and advanced diabetic nephropathy, and in 11 control kidneys. Findings were quantified by image analysis. Human mesangial cells were cultured with normal or high glucose, albumin or glycated albumin (Amadori product), +/−THBS1 or CTGF antisense oligonucleotides, or with peptide W, an inhibitor of TGFB1 bioactivation by THBS1. Proteins were measured by western blot analysis or ELISA.

Results

In glomeruli of normal kidneys, mRNA and protein levels for THBS1, latent-TGFB1 and CTGF were low. They were increased in the incipient stage of diabetic nephropathy, predominantly in mesangial areas, with further increases at later stages of the disease. Little or no active TGFB1 immunostaining was detected prior to manifest diabetic nephropathy. In contrast to high-glucose conditions, increases in fibronectin synthesis that were stimulated by glycated albumin were not dependent on THBS1 activation of latent TGFB1. However, increased fibronectin synthesis in both conditions required CTGF.

Conclusions/interpretation

Increased glomerular expression of all three factors occurs from the earliest stage of diabetic nephropathy. In contrast to THBS1, CTGF is required for mesangial synthesis of fibronectin stimulated by high glucose or glycated albumin, and is thus a potential therapeutic target.
Literatur
1.
Zurück zum Zitat Mogensen CE, Christensen CK (1984) Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311:89–93PubMedCrossRef Mogensen CE, Christensen CK (1984) Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311:89–93PubMedCrossRef
2.
Zurück zum Zitat The Diabetic Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef The Diabetic Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef
3.
Zurück zum Zitat UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef
4.
Zurück zum Zitat Mogensen CE, Christensen CK, Vittinghus E (1983) The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 32(Suppl. 2):64–78PubMed Mogensen CE, Christensen CK, Vittinghus E (1983) The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 32(Suppl. 2):64–78PubMed
5.
Zurück zum Zitat Sharma K, Ziyadeh FN (1995) Hyperglycemia and diabetic kidney disease. Diabetes 44:1139–1146PubMedCrossRef Sharma K, Ziyadeh FN (1995) Hyperglycemia and diabetic kidney disease. Diabetes 44:1139–1146PubMedCrossRef
6.
Zurück zum Zitat Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820CrossRefPubMed Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820CrossRefPubMed
7.
Zurück zum Zitat Border WA, Noble NA (1997) TGF-beta in kidney fibrosis: a target for gene therapy. Kidney Int 51:1388–1396PubMedCrossRef Border WA, Noble NA (1997) TGF-beta in kidney fibrosis: a target for gene therapy. Kidney Int 51:1388–1396PubMedCrossRef
8.
Zurück zum Zitat Ito Y, Aten J, Bende RJ et al (1998) Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 53:853–861CrossRefPubMed Ito Y, Aten J, Bende RJ et al (1998) Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 53:853–861CrossRefPubMed
9.
Zurück zum Zitat Abdel-Wahab N, Yevdokimova N, Weston BS et al. (2001) Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem J 359:77–87CrossRefPubMed Abdel-Wahab N, Yevdokimova N, Weston BS et al. (2001) Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem J 359:77–87CrossRefPubMed
10.
Zurück zum Zitat Sharma K, Jin Y, Guo J, Ziyadeh FN (1996) Neutralization of TGFβ by anti-TGFβ antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STR-induced diabetic mice. Diabetes 45:522–530PubMedCrossRef Sharma K, Jin Y, Guo J, Ziyadeh FN (1996) Neutralization of TGFβ by anti-TGFβ antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STR-induced diabetic mice. Diabetes 45:522–530PubMedCrossRef
11.
Zurück zum Zitat Twigg SM, Chenn MM, Joly AH et al (2001) Advanced glycosylation end-products upregulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology 142:1760–1769PubMedCrossRef Twigg SM, Chenn MM, Joly AH et al (2001) Advanced glycosylation end-products upregulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology 142:1760–1769PubMedCrossRef
12.
Zurück zum Zitat Abdel Wahab N, Harper K, Mason R (1996) Expression of extracellular matrix molecules in human mesangial cells in response to prolonged hyperglycaemia. Biochem J 316:985–992PubMed Abdel Wahab N, Harper K, Mason R (1996) Expression of extracellular matrix molecules in human mesangial cells in response to prolonged hyperglycaemia. Biochem J 316:985–992PubMed
13.
Zurück zum Zitat Abdel-Wahab N, Weston BS, Roberts T, Mason RM (2002) Connective tissue growth factor and regulation of the mesangial cell cycle: role in cellular hypertrophy. J Am Soc Nephrol 13:2437–2445CrossRefPubMed Abdel-Wahab N, Weston BS, Roberts T, Mason RM (2002) Connective tissue growth factor and regulation of the mesangial cell cycle: role in cellular hypertrophy. J Am Soc Nephrol 13:2437–2445CrossRefPubMed
14.
Zurück zum Zitat Grotendorst GR, Okochi H, Hayashi N (1996) A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ 7:469–480PubMed Grotendorst GR, Okochi H, Hayashi N (1996) A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ 7:469–480PubMed
15.
Zurück zum Zitat Duncan MR, Frazier KS, Abramson S et al (1999) Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. FASEB J 13:1774–1786PubMed Duncan MR, Frazier KS, Abramson S et al (1999) Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. FASEB J 13:1774–1786PubMed
16.
Zurück zum Zitat Koli K, Saharinen J, Hyytiainen M, Penttinen C, Keski-Oja J (2001) Latency, activation, and binding proteins of TGF-beta. Microsc Res Tech 52:354–362CrossRefPubMed Koli K, Saharinen J, Hyytiainen M, Penttinen C, Keski-Oja J (2001) Latency, activation, and binding proteins of TGF-beta. Microsc Res Tech 52:354–362CrossRefPubMed
17.
Zurück zum Zitat Yevdokimova N, Abdel-Wahab N, Mason RM (2001) Thrombospondin-1 is the key activator of TGF-β1 in human mesangial cells exposed to high glucose. J Am Soc Nephrol 12:703–712PubMed Yevdokimova N, Abdel-Wahab N, Mason RM (2001) Thrombospondin-1 is the key activator of TGF-β1 in human mesangial cells exposed to high glucose. J Am Soc Nephrol 12:703–712PubMed
18.
Zurück zum Zitat Daniel C, Wiede J, Krutzsch HC et al (2004) Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo. Kidney Int 65:459–468CrossRefPubMed Daniel C, Wiede J, Krutzsch HC et al (2004) Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo. Kidney Int 65:459–468CrossRefPubMed
19.
Zurück zum Zitat Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM et al (1998) Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93:1159–1170CrossRefPubMed Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM et al (1998) Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93:1159–1170CrossRefPubMed
20.
Zurück zum Zitat Mogensen CE (1987) Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 31:673–689PubMedCrossRef Mogensen CE (1987) Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 31:673–689PubMedCrossRef
21.
Zurück zum Zitat Schaefer L, Raslik I, Gröne HJ et al (2001) Small proteoglycans in human diabetic nephropathy: discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican and fibromodulin. FASEB J 15:559–561PubMed Schaefer L, Raslik I, Gröne HJ et al (2001) Small proteoglycans in human diabetic nephropathy: discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican and fibromodulin. FASEB J 15:559–561PubMed
22.
Zurück zum Zitat Schaefer L, Hausser H, Altenburger M et al (1998) Decorin, biglycan and their endocytosis receptor in rat renal cortex. Kidney Int 54:1529–1541CrossRefPubMed Schaefer L, Hausser H, Altenburger M et al (1998) Decorin, biglycan and their endocytosis receptor in rat renal cortex. Kidney Int 54:1529–1541CrossRefPubMed
23.
Zurück zum Zitat Tsang ML, Zhou L, Zheng BL et al (1995) Characterization of recombinant soluble human transforming growth factor-β receptor type II (rhTGF-β sRII).Cytokine 7:389–397CrossRefPubMed Tsang ML, Zhou L, Zheng BL et al (1995) Characterization of recombinant soluble human transforming growth factor-β receptor type II (rhTGF-β sRII).Cytokine 7:389–397CrossRefPubMed
24.
Zurück zum Zitat Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA (1994) Transforming growth factor-β activation in irradiated murine mammary gland. J Clin Invest 93:892–899PubMedCrossRef Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA (1994) Transforming growth factor-β activation in irradiated murine mammary gland. J Clin Invest 93:892–899PubMedCrossRef
25.
Zurück zum Zitat Flanders KC, Thompson NL, Cissel DS et al (1989) Transforming growth factor-β1: histochemical localization with antibodies to different epitopes. J Cell Biol 108:653–660CrossRefPubMed Flanders KC, Thompson NL, Cissel DS et al (1989) Transforming growth factor-β1: histochemical localization with antibodies to different epitopes. J Cell Biol 108:653–660CrossRefPubMed
26.
Zurück zum Zitat Murphy-Ullrich JE, Poczatek M (2000) Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 11:59–69CrossRefPubMed Murphy-Ullrich JE, Poczatek M (2000) Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 11:59–69CrossRefPubMed
27.
Zurück zum Zitat Border WA, Yamamoto T, Noble NA (1996) Transforming growth factor beta in diabetic nephropathy. Diabetes Metab Rev 12:309–339CrossRefPubMed Border WA, Yamamoto T, Noble NA (1996) Transforming growth factor beta in diabetic nephropathy. Diabetes Metab Rev 12:309–339CrossRefPubMed
28.
Zurück zum Zitat Hong SW, Isono M, Chen S et al (2001) Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 158:1653–1663PubMed Hong SW, Isono M, Chen S et al (2001) Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 158:1653–1663PubMed
29.
Zurück zum Zitat Ziyadeh FN, Hoffman BB, Han DC et al (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015–8020CrossRefPubMed Ziyadeh FN, Hoffman BB, Han DC et al (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015–8020CrossRefPubMed
30.
Zurück zum Zitat Hill C, Flyvbjerg A, Rasch R, Bak M, Logan A (2001) Transforming growth factor-beta2 antibody attenuates fibrosis in the experimental diabetic rat kidney. J Endocrinol 170:647–651CrossRefPubMed Hill C, Flyvbjerg A, Rasch R, Bak M, Logan A (2001) Transforming growth factor-beta2 antibody attenuates fibrosis in the experimental diabetic rat kidney. J Endocrinol 170:647–651CrossRefPubMed
31.
Zurück zum Zitat Wang SN, Hirschberg R (2000) Growth factor ultrafiltration in experimental diabetic nephropathy contributes to interstitial fibrosis. Am J Physiol Renal Physiol 278:F554–F560PubMed Wang SN, Hirschberg R (2000) Growth factor ultrafiltration in experimental diabetic nephropathy contributes to interstitial fibrosis. Am J Physiol Renal Physiol 278:F554–F560PubMed
32.
Zurück zum Zitat Holmes DI, Abdel Wahab N, Mason RM (1997) Identification of glucose-regulated genes in human mesangial cells by mRNA differential display. Biochem Biophys Res Commun 238:179–184CrossRefPubMed Holmes DI, Abdel Wahab N, Mason RM (1997) Identification of glucose-regulated genes in human mesangial cells by mRNA differential display. Biochem Biophys Res Commun 238:179–184CrossRefPubMed
33.
Zurück zum Zitat Poczatek MH, Hugo C, Darley-Usmar V, Murphy-Ullrich JE (2000) Glucose stimulation of transforming growth factor-beta bioactivity in mesangial cells is mediated by thrombospondin-1. Am J Pathol 157:1353–1363PubMed Poczatek MH, Hugo C, Darley-Usmar V, Murphy-Ullrich JE (2000) Glucose stimulation of transforming growth factor-beta bioactivity in mesangial cells is mediated by thrombospondin-1. Am J Pathol 157:1353–1363PubMed
34.
Zurück zum Zitat Riser BL, Denichilo M, Cortes P et al (2000) Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 11:25–38CrossRefPubMed Riser BL, Denichilo M, Cortes P et al (2000) Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 11:25–38CrossRefPubMed
35.
Zurück zum Zitat Raptis AE, Viberti G (2001) Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 109(Suppl 2):S424–S437CrossRefPubMed Raptis AE, Viberti G (2001) Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 109(Suppl 2):S424–S437CrossRefPubMed
36.
Zurück zum Zitat Blom IE, Goldschmeding R, Leask A (2002) Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol 21:473–482CrossRefPubMed Blom IE, Goldschmeding R, Leask A (2002) Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol 21:473–482CrossRefPubMed
37.
Zurück zum Zitat Weston BS, Abdel Wahab N, Mason RM (2003) CTGF mediates TGF-β induced fibronectin matrix deposition by upregulating active α5β1 integrin in human mesangial cells. J Am Soc Nephrol 14:601–610CrossRefPubMed Weston BS, Abdel Wahab N, Mason RM (2003) CTGF mediates TGF-β induced fibronectin matrix deposition by upregulating active α5β1 integrin in human mesangial cells. J Am Soc Nephrol 14:601–610CrossRefPubMed
38.
Zurück zum Zitat Crean JK, Finlay D, Murphy M et al (2002) The role of p42/44 MAPK and protein kinase B in connective tissue growth factor induced extracellular matrix protein production, cell migration, and actin cytoskeletal rearrangement in human mesangial cells. J Biol Chem 277:44187–44194CrossRefPubMed Crean JK, Finlay D, Murphy M et al (2002) The role of p42/44 MAPK and protein kinase B in connective tissue growth factor induced extracellular matrix protein production, cell migration, and actin cytoskeletal rearrangement in human mesangial cells. J Biol Chem 277:44187–44194CrossRefPubMed
39.
Zurück zum Zitat Wahab NA, Weston BS, Mason RM (2004) Connective tissue growth factor (CTGF, CCN2) interacts with and activates the tyrosine kinase receptor TrkA. J Am Soc Nephrol 16:340–351CrossRefPubMed Wahab NA, Weston BS, Mason RM (2004) Connective tissue growth factor (CTGF, CCN2) interacts with and activates the tyrosine kinase receptor TrkA. J Am Soc Nephrol 16:340–351CrossRefPubMed
40.
Zurück zum Zitat Johnsen SA, Subramaniam M, Janknecht R, Spelsberg TC (2002) TGF beta inducible early gene enhances TGFbeta/Smad-dependent transcriptional responses. Oncogene 21:5783–5790CrossRefPubMed Johnsen SA, Subramaniam M, Janknecht R, Spelsberg TC (2002) TGF beta inducible early gene enhances TGFbeta/Smad-dependent transcriptional responses. Oncogene 21:5783–5790CrossRefPubMed
41.
Zurück zum Zitat Kavsak P, Rasmussen RK, Causing CG et al (2000) Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 6:1365–1375CrossRefPubMed Kavsak P, Rasmussen RK, Causing CG et al (2000) Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 6:1365–1375CrossRefPubMed
42.
Zurück zum Zitat Wahab NA, Mason RM (2004) Connective tissue growth factor and renal diseases: some answers, more questions. Curr Opin Nephrol Hypertens 13:52–58 Wahab NA, Mason RM (2004) Connective tissue growth factor and renal diseases: some answers, more questions. Curr Opin Nephrol Hypertens 13:52–58
43.
Zurück zum Zitat Wahab NA, Weston BS, Mason, RM (2005) Modulation of TGFβ/Smad signaling pathway by CTGF/CCN2. Exp Cell Res 307:305–314CrossRefPubMed Wahab NA, Weston BS, Mason, RM (2005) Modulation of TGFβ/Smad signaling pathway by CTGF/CCN2. Exp Cell Res 307:305–314CrossRefPubMed
44.
Zurück zum Zitat Schrijvers BF, De Vriese AS, Flyvbjerg A (2004) From hyperglycaemia to diabetic kidney disease: the role of metabolic, haemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 25:971–1010PubMedCrossRef Schrijvers BF, De Vriese AS, Flyvbjerg A (2004) From hyperglycaemia to diabetic kidney disease: the role of metabolic, haemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 25:971–1010PubMedCrossRef
45.
Zurück zum Zitat Schleicher ED, Weigert C (2000) Role of the hexosamine biosynthetic pathway in diabetic nephropathy. Kidney Int Suppl 77:S13–S18CrossRef Schleicher ED, Weigert C (2000) Role of the hexosamine biosynthetic pathway in diabetic nephropathy. Kidney Int Suppl 77:S13–S18CrossRef
46.
Zurück zum Zitat Kapor-Drezgic J, Zhou X, Babazono T, Dlugosz JA, Hohman T, Whiteside C (1999) Effect of high glucose on mesangial cell protein kinase C-delta and -epsilon is polyol pathway-dependent. J Am Soc Nephrol 10:1193–1203PubMed Kapor-Drezgic J, Zhou X, Babazono T, Dlugosz JA, Hohman T, Whiteside C (1999) Effect of high glucose on mesangial cell protein kinase C-delta and -epsilon is polyol pathway-dependent. J Am Soc Nephrol 10:1193–1203PubMed
47.
Zurück zum Zitat Whiteside CI, Dlugosz JA (2002) Mesangial cell protein kinase C isozyme activation in the diabetic milieu. Am J Physiol Renal Physiol 282:F975–F980PubMed Whiteside CI, Dlugosz JA (2002) Mesangial cell protein kinase C isozyme activation in the diabetic milieu. Am J Physiol Renal Physiol 282:F975–F980PubMed
48.
Zurück zum Zitat Wu VY, Cohen MP (1995) Evidence for a ligand receptor system mediating the biologic effect of glycated albumin in glomerular mesangial cells. Biochem Biophys Res Commun 207:521–528CrossRefPubMed Wu VY, Cohen MP (1995) Evidence for a ligand receptor system mediating the biologic effect of glycated albumin in glomerular mesangial cells. Biochem Biophys Res Commun 207:521–528CrossRefPubMed
49.
Zurück zum Zitat Cohen MP, Ziyadeh FN, Lautenslager GT, Cohen JA, Shearman CW (1999) Glycated albumin stimulation of PKC-β activity is linked to increased collagen IV in mesangial cells. Am J Physiol Renal Physiol 276:F684–F690 Cohen MP, Ziyadeh FN, Lautenslager GT, Cohen JA, Shearman CW (1999) Glycated albumin stimulation of PKC-β activity is linked to increased collagen IV in mesangial cells. Am J Physiol Renal Physiol 276:F684–F690
50.
Zurück zum Zitat Mason RM, Wahab NA (2003) Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 14:1358–1373CrossRefPubMed Mason RM, Wahab NA (2003) Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 14:1358–1373CrossRefPubMed
Metadaten
Titel
Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli
verfasst von
N. A. Wahab
L. Schaefer
B. S. Weston
O. Yiannikouris
A. Wright
A. Babelova
R. Schaefer
R. M. Mason
Publikationsdatum
01.12.2005
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 12/2005
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-0006-5

Weitere Artikel der Ausgabe 12/2005

Diabetologia 12/2005 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.